Transgene SA - Product Pipeline Review - 2014

Published: Nov, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Transgene SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Transgene SA - Product Pipeline Review - 2014', provides an overview of the Transgene SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Transgene SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Transgene SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Transgene SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Transgene SA's pipeline products

Reasons to buy

- Evaluate Transgene SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Transgene SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Transgene SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Transgene SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Transgene SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Transgene SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Transgene SA Snapshot 5
Transgene SA Overview 5
Key Information 5
Key Facts 5
Transgene SA - Research and Development Overview 6
Key Therapeutic Areas 6
Transgene SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Transgene SA - Pipeline Products Glance 13
Transgene SA - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Transgene SA - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Transgene SA - Drug Profiles 16
TG-4010 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
pexastimogene devacirepvec 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
TG-1042 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
TG-4001 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
TG-4040 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Vaccine for Undisclosed Indication 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
MVA-TB 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
TG-1050 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
TG-3003 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
TG-6002 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Transgene SA - Pipeline Analysis 32
Transgene SA - Pipeline Products by Target 32
Transgene SA - Pipeline Products by Route of Administration 33
Transgene SA - Pipeline Products by Molecule Type 34
Transgene SA - Pipeline Products by Mechanism of Action 35
Transgene SA - Recent Pipeline Updates 36
Transgene SA - Dormant Projects 45
Transgene SA - Discontinued Pipeline Products 46
Discontinued Pipeline Product Profiles 46
TG-1042 46
Transgene SA - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49

List of Tables
Transgene SA, Key Information 5
Transgene SA, Key Facts 5
Transgene SA - Pipeline by Indication, 2014 8
Transgene SA - Pipeline by Stage of Development, 2014 9
Transgene SA - Monotherapy Products in Pipeline, 2014 10
Transgene SA - Partnered Products in Pipeline, 2014 11
Transgene SA - Partnered Products/ Combination Treatment Modalities, 2014 12
Transgene SA - Phase II, 2014 13
Transgene SA - Phase I, 2014 14
Transgene SA - Preclinical, 2014 15
Transgene SA - Pipeline by Target, 2014 32
Transgene SA - Pipeline by Route of Administration, 2014 33
Transgene SA - Pipeline by Molecule Type, 2014 34
Transgene SA - Pipeline Products by Mechanism of Action, 2014 35
Transgene SA - Recent Pipeline Updates, 2014 36
Transgene SA - Dormant Developmental Projects,2014 45
Transgene SA - Discontinued Pipeline Products, 2014 46
Transgene SA, Subsidiaries 47